These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 19896875)

  • 1. My child has Leber congenital amaurosis: why is he/she not eligible for gene therapy trials?
    Héon E
    J AAPOS; 2009 Dec; 13(6):533-4. PubMed ID: 19896875
    [No Abstract]   [Full Text] [Related]  

  • 2. Leber congenital amaurosis: clinical correlations with genotypes, gene therapy trials update, and future directions.
    Chung DC; Traboulsi EI
    J AAPOS; 2009 Dec; 13(6):587-92. PubMed ID: 20006823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Seeing is believing: gene therapy shows promise for ocular disorders.
    Friedrich MJ
    JAMA; 2010 Oct; 304(14):1543-5. PubMed ID: 20940376
    [No Abstract]   [Full Text] [Related]  

  • 4. Gene augmentation trials using the Rpe65-deficient dog: contributions towards development and refinement of human clinical trials.
    Petersen-Jones SM; Annear MJ; Bartoe JT; Mowat FM; Barker SE; Smith AJ; Bainbridge JW; Ali RR
    Adv Exp Med Biol; 2012; 723():177-82. PubMed ID: 22183331
    [No Abstract]   [Full Text] [Related]  

  • 5. Which Leber congenital amaurosis patients are eligible for gene therapy trials?
    Drack AV; Johnston R; Stone EM
    J AAPOS; 2009 Oct; 13(5):463-5. PubMed ID: 19840725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Manufacturing and regulatory strategies for clinical AAV2-hRPE65.
    Wright JF; Wellman J; High KA
    Curr Gene Ther; 2010 Oct; 10(5):341-9. PubMed ID: 20712582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical gene therapy for the treatment of RPE65-associated Leber congenital amaurosis.
    Stein L; Roy K; Lei L; Kaushal S
    Expert Opin Biol Ther; 2011 Mar; 11(3):429-39. PubMed ID: 21299439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular anthropology meets genetic medicine to treat blindness in the North African Jewish population: human gene therapy initiated in Israel.
    Banin E; Bandah-Rozenfeld D; Obolensky A; Cideciyan AV; Aleman TS; Marks-Ohana D; Sela M; Boye S; Sumaroka A; Roman AJ; Schwartz SB; Hauswirth WW; Jacobson SG; Hemo I; Sharon D
    Hum Gene Ther; 2010 Dec; 21(12):1749-57. PubMed ID: 20604683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The phenotype of Severe Early Childhood Onset Retinal Dystrophy (SECORD) from mutation of RPE65 and differentiation from Leber congenital amaurosis.
    Weleber RG; Michaelides M; Trzupek KM; Stover NB; Stone EM
    Invest Ophthalmol Vis Sci; 2011 Jan; 52(1):292-302. PubMed ID: 20811047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Available Evidence on Leber Congenital Amaurosis and Gene Therapy.
    Alkharashi M; Fulton AB
    Semin Ophthalmol; 2017; 32(1):14-21. PubMed ID: 27686653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leber congenital amaurosis due to RPE65 mutations and its treatment with gene therapy.
    Cideciyan AV
    Prog Retin Eye Res; 2010 Sep; 29(5):398-427. PubMed ID: 20399883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene therapy for eye as regenerative medicine? Lessons from RPE65 gene therapy for Leber's Congenital Amaurosis.
    Rakoczy EP; Narfström K
    Int J Biochem Cell Biol; 2014 Nov; 56():153-7. PubMed ID: 25286304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Gene therapy for vision restoration in patients with Leber congenital amaurosis (LCA) due to RPE65 gene mutations: beginning the phase IV trial].
    Chacón-Camacho ÓF; Zenteno JC
    Gac Med Mex; 2017; 153(2):276-278. PubMed ID: 28474714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preserved outer retina in AIPL1 Leber's congenital amaurosis: implications for gene therapy.
    Aboshiha J; Dubis AM; van der Spuy J; Nishiguchi KM; Cheeseman EW; Ayuso C; Ehrenberg M; Simonelli F; Bainbridge JW; Michaelides M
    Ophthalmology; 2015 Apr; 122(4):862-4. PubMed ID: 25596619
    [No Abstract]   [Full Text] [Related]  

  • 15. Gene therapy for RPE65-related retinal disease.
    Miraldi Utz V; Coussa RG; Antaki F; Traboulsi EI
    Ophthalmic Genet; 2018 Dec; 39(6):671-677. PubMed ID: 30335549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Ocular Gene Therapy in an Italian Patient Affected by Congenital Leber Amaurosis Type 2 Treated in Both Eyes.
    Testa F; Maguire AM; Rossi S; Marshall K; Auricchio A; Melillo P; Bennett J; Simonelli F
    Adv Exp Med Biol; 2016; 854():533-9. PubMed ID: 26427456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Massively parallel sequencing for early molecular diagnosis in Leber congenital amaurosis.
    Coppieters F; De Wilde B; Lefever S; De Meester E; De Rocker N; Van Cauwenbergh C; Pattyn F; Meire F; Leroy BP; Hellemans J; Vandesompele J; De Baere E
    Genet Med; 2012 Jun; 14(6):576-85. PubMed ID: 22261762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased levels of gene therapy may not be beneficial in retinal disease.
    Townes-Anderson E
    Proc Natl Acad Sci U S A; 2013 May; 110(19):E1705. PubMed ID: 23553840
    [No Abstract]   [Full Text] [Related]  

  • 19. Reply to Townes-Anderson: RPE65 gene therapy does not alter the natural history of retinal degeneration.
    Cideciyan AV; Jacobson SG; Beltran WA; Hauswirth WW; Aguirre GD
    Proc Natl Acad Sci U S A; 2013 May; 110(19):E1706. PubMed ID: 23789127
    [No Abstract]   [Full Text] [Related]  

  • 20. Investor Outlook: Focus on Upcoming LCA2 Gene Therapy Phase III Results.
    Schimmer J; Breazzano S
    Hum Gene Ther Clin Dev; 2015 Sep; 26(3):144-9. PubMed ID: 26390089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.